Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...

Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...

Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...

AstraZeneca CEO Pascal Soriot affirms commitment to China despite investigation involving China president Leon Wang and other ...

Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...

Diverge, a startup helping Medicaid members access care, raised $52 million led by Alphabet's GV. The company, launched in ...

Trace Neuroscience, a startup spun out of Maze Therapeutics' pipeline, broke cover Tuesday morning with $101 million in ...

No­var­tis will pay $150 mil­lion up­front to Schrödinger, in a pact an­nounced Tues­day to work to­geth­er on sev­er­al ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

AstraZeneca announces $2 billion investment to create 1,000 new US jobs, adding to previous $1.5 billion commitment. The $3.5 ...

Bayer CEO Bill Anderson affirmed plans to manage Xarelto's generic competition decline, as shares hit record low following Q3 ...

Apollo Therapeutics will pay $12M upfront and up to $926M in milestone payments to Sunshine Lake Pharma for worldwide rights (excluding China) to their FGF21/GLP-1 dual receptor agonist ...